Records 1-30 (of 836 Records) |
Query Trace: all[original query] |
---|
Application of the advanced lung cancer inflammation index for patients with coronavirus disease 2019 pneumonia: Combined risk prediction model with advanced lung cancer inflammation index, computed tomography and chest radiograph. Inoue Akitoshi, et al. Experimental and therapeutic medicine 2022 0 0. (6) 388 ![]() ![]() |
Identifying the specific-targeted marine cerebrosides against SARS-CoV-2: an integrated computational approach. Zahran Eman Maher, et al. RSC advances 2022 0 0. (57) 36042-36059 ![]() ![]() |
Identifying Potential Gene Defect Patterns Related to COVID-19 Based on Pharmacological and Bioinformatics Analysis for Lung Adenocarcinoma. Lou Hongqiang, et al. International journal of general medicine 2022 0 0. 4285-4301 ![]() ![]() |
COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge. Bronstein Yotam, et al. Cancer cell 2022 0 0. ![]() |
Recurrent neural network models (CovRNN) for predicting outcomes of patients with COVID-19 on admission to hospital: model development and validation using electronic health record data. Rasmy Laila, et al. The Lancet. Digital health 2022 0 0. ![]() ![]() |
Increased Number Of Colorectal Interval Cancers In Lynch Syndrome After The SARS-CoV-2 Pandemic. A Survey-based Study. Russo Michele, et al. Digestive diseases (Basel, Switzerland) 2022 0 0. ![]() ![]() |
TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19. Harford Joe B, et al. Viruses 2022 0 0. (4) ![]() ![]() |
The Role of Immune Regulatory Molecules in COVID-19. Khalifehzadeh-Esfahani Zahra, et al. Viral immunology 2022 0 0. ![]() ![]() ![]() |
Pulmonary embolism in pediatric and adolescent patients with COVID-19 infection during the SARS-CoV-2 delta wave. Cohen Clay T, et al. Pediatric blood & cancer 2022 0 0. e29721 ![]() ![]() |
T-cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity. Elyanow Rebecca et al. JCI insight 2022 4 ![]() |
Longitudinal COVID-19 vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer PC Mack et al, Cell, April 19 2022 ![]() |
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Chang Andres, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 0 0. JCO2200088 ![]() ![]() ![]() ![]() |
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study. Lasagna A, et al. ESMO open 2022 0 0. (2) 100458 ![]() ![]() ![]() |
Vaccinating Children with Disabilities Against COVID-19 CDC, April 2022 ![]()
CDC recommends everyone 5 years and older get vaccinated against COVID-19 - including children with disabilities who may be at a higher risk for severe illness from COVID-19. Many children with disabilities have underlying medical conditions - such as lung, heart, or kidney disease, a weakened immune system, cancer, diabetes, some blood diseases, or conditions of the muscular or central nervous system - which put them at increased risk for severe illness from COVID-19.
|
SARS-CoV-2 Omicron Variant in Patients With Chronic Myeloid Leukemia: A Retrospective Study. Ali Elrazi A, et al. Cureus 2022 0 0. (4) e23863 ![]() ![]() |
FDG PET/CT radiomics as a tool to differentiate between reactive axillary lymphadenopathy following COVID-19 vaccination and metastatic breast cancer axillary lymphadenopathy: a pilot study. Eifer Michal, et al. European radiology 2022 0 0. ![]() ![]() ![]() |
Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches. Ahmed Fee Faysal, et al. PloS one 2022 0 0. (4) e0266124 ![]() ![]() ![]() ![]() |
SARS-CoV-2 -specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. Woldemeskel Bezawit A, et al. JCI insight 2022 0 0. ![]() ![]() ![]() ![]() |
Mutational Analysis of Interleukin-11 and its Consequences on Cancer and COVID-19 Related Cytokine Storm -An Extensive Molecular Dynamics Study. Ray Sujay, et al. Protein and peptide letters 2022 0 0. ![]() ![]() |
FULMINANT MYOCARDITIS IN A PATIENT WITH A LUNG ADENOCARCINOMA AFTER THE THIRD DOSE OF MODERN COVID-19 VACCINE. A CASE REPORT AND LITERATURE REVIEW. Brage Eduardo Terán, et al. Current problems in cancer. Case reports 2022 0 0. 100153 ![]() |
Response-Liminality and the Mirage of Settlement. Hooker Claire, et al. Journal of bioethical inquiry 2022 0 0. |
Landscape of Molecular Crosstalk Perturbation between Lung Cancer and COVID-19. Kuchi Aditi, et al. International journal of environmental research and public health 2022 0 0. (6) ![]() |
Principles and Applications of CRISPR Toolkit in Virus Manipulation, Diagnosis, and Virus-Host Interactions. Jamehdor Saleh, et al. Cells 2022 0 0. (6) ![]() ![]() ![]() |
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Lim Sean H, et al. Nature cancer 2022 0 0. ![]() ![]() ![]() ![]() |
Open Reading Frame-3a gene of the 2019 novel coronavirus inhibits the occurrence and development of colorectal cancer. Shuwen Han, et al. Discover. Oncology 2022 0 0. (1) 14 ![]() ![]() |
Recognition of Peripheral Lung Cancer and Focal Pneumonia on Chest Computed Tomography Images Based on Convolutional Neural Network. Cheng Xiaoyue, et al. Technology in cancer research & treatment 2022 0 0. 15330338221085375 ![]() |
Vaccine hesitancy in the post-vaccination COVID-19 era: a machine learning and statistical analysis driven study. Gupta Himanshu, et al. Evolutionary intelligence 2022 0 0. 1-19 ![]() ![]() ![]() |
COVID-19 Booster Vaccine Equity for Patients with Cancer. Prasad Rahul N, et al. Advances in radiation oncology 2022 0 0. 100939 ![]() ![]() ![]() |
COVID-19 and resilience of healthcare systems in ten countries C Arsenault et al, Nature Medicine, March 14, 2022
We used an interrupted time series design to assess the immediate effect of the pandemic on 31 health services in two low-income (Ethiopia and Haiti), six middle-income? (Ghana, Lao People’s Democratic Republic, Mexico, Nepal, South Africa and Thailand) and high-income (Chile and South Korea) countries. Despite efforts to maintain health services, disruptions of varying magnitude and duration were found in every country, with no clear patterns by country income group or pandemic intensity. Disruptions in health services often preceded COVID-19 waves. Cancer screenings, TB screening and detection and HIV testing were most affected (26–96% declines). Total outpatient visits declined by 9–40% at national levels and remained lower than predicted by the end of 2020. Maternal health services were disrupted in approximately half of the countries, with declines ranging from 5% to 33%. Child vaccinations were disrupted for shorter periods.
|
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety A Fendler et al, Nat Rev Oncology, March 11, 2022 ![]()
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events.
|
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Jul 25, 2022
- Page last updated:Jan 28, 2023
- Content source: